← Back to Clinical Trials
Recruiting NCT07112807

NCT07112807 Comparison of the Effects of ShoulderSphere Exercises and Bodyblade Exercises

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07112807
Status Recruiting
Phase
Sponsor Gazi University
Condition Scapular Dyskinesis
Study Type INTERVENTIONAL
Enrollment 45 participants
Start Date 2024-10-21
Primary Completion 2025-08-29

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 25 Years
Study Type INTERVENTIONAL
Interventions
Strengthening ExercisesShoulderSphere Exercises and Resistive ExercisesBodyblade Exercises and Resistive Exercises

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 45 participants in total. It began in 2024-10-21 with a primary completion date of 2025-08-29.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The scapula functions as a bridge connecting the upper extremity and the trunk. It contributes to more efficient and functional upper extremity movements. Scapular dyskinesis, defined as a deviation from the resting position and movements of the scapula, can reduce shoulder proprioception, scapular muscle endurance, and upper extremity function. The aim is to compare the long-term effects of exercises performed using the ShoulderSphere and the Bodyblade, which provide oscillatory stimulation and vibration, enhancing neuromuscular control that improves these factors. Forty-five volunteers with asymptomatic scapular dyskinesis will be randomized into three groups. The control group will receive resistive scapular muscle exercises. The ShoulderSphere group will receive exercises performed using the ShoulderSphere in addition to the control group. The Bodyblade group will receive exercises performed using the Bodyblade in addition to the control group. Pre- and post-treatment proprioception, muscle endurance, and upper extremity function will be assessed, and the groups will be compared. The study results will analyze which method is more effective in the rehabilitation program of individuals with asymptomatic scapular dyskinesis and determine its inclusion in the rehabilitation program.

Eligibility Criteria

Inclusion Criteria: * Having scapular dyskinesia * No shoulder or neck pain Exclusion Criteria: * Positive Neer, Jobe, or Hawkins tests * Shoulder instability * Painful arch during arm elevation * Painful passive or resisted shoulder external rotation at 90° shoulder abduction * History of shoulder fracture or surgery * Presence of shoulder pain in the last 6 months * Presence of cognitive or neurological impairment

Contact & Investigator

Central Contact

Tuğçe Çoban, MSc

✉ fzttugce@yahoo.com

📞 5454098540

Principal Investigator

Tuğçe Çoban, MSc

STUDY DIRECTOR

Gazi University

Frequently Asked Questions

Who can join the NCT07112807 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 25 Years, studying Scapular Dyskinesis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07112807 currently recruiting?

Yes, NCT07112807 is actively recruiting participants. Contact the research team at fzttugce@yahoo.com for enrollment information.

Where is the NCT07112807 trial being conducted?

This trial is being conducted at Ankara, Turkey (Türkiye).

Who is sponsoring the NCT07112807 clinical trial?

NCT07112807 is sponsored by Gazi University. The principal investigator is Tuğçe Çoban, MSc at Gazi University. The trial plans to enroll 45 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology